Ustekinumab Market

Ustekinumab API market is projected to grow at a CAGR of 7.5% between 2025 and 2035, primarily due to the increasing prevalence of autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Furthermore, the market growth is driven by rising awareness of biologic treatments, advancements in healthcare infrastructure, and the increasing adoption of immunotherapies. Ustekinumab, marketed under the brand name Stelara, has become a cornerstone in the treatment of these chronic conditions, contributing to its strong demand in the global market.

The key segment within the ustekinumab API market is the injectable formulation, as this remains the most common method of administration for Ustekinumab. Injectables are preferred due to their effectiveness in delivering the biologic agent directly into the bloodstream, ensuring a fast and reliable therapeutic response. In contrast, oral formulations are still in the experimental stages, with limited availability in the market.

Geographically, North American region, particularly the US, holds the largest share of the Ustekinumab API market. This is due to the high prevalence of autoimmune diseases, advanced healthcare systems, and the wide acceptance of biologic therapies. Europe also represents a significant market, with key countries like Germany, the UK, and France showing strong demand for Ustekinumab-based treatments. In the Asia-Pacific region, countries such as Japan, China, and India are witnessing an increasing uptake of biologic treatments, contributing to the growth of the market.

Prominent players in the market include Johnson & Johnson (Janssen Pharmaceuticals), the originator of Ustekinumab, as well as Samsung Biologics, Boehringer Ingelheim, and Fujifilm Diosynth Biotechnologies, which are involved in the production and supply of Ustekinumab APIs. These companies are actively involved in expanding their manufacturing capabilities and exploring new formulations to meet the growing global demand.